14138 Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices 

Types of respondents 

Estimated 

number of respondents 

Estimated 

number of responses per 

respondent 

Average burden hours per 

response 

Estimated total 

annual burden 

hours requested 

Researchers, Physicians, Other Health Care Providers, Librarians, Students, General Public ................................................................................... 27,910 1 .129 3,607 

The annualized cost to respondents 

for each year of the generic clearance is 

estimated to be $23,126. There are no 

Capital Costs, Operating Costs, and/or 

Maintenance Costs to report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact: David Sharlip, 

National Library of Medicine, Building 

38A, Room B2N12, 8600 Rockville Pike, 

Bethesda, MD 20894, or call non-toll 

free number 301–402–9680 or E-mail 

your request to sharlipd@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Dated: March 23, 2009. 

Betsy L. Humphreys, M.L.S., 

Deputy Director, National Library of 

Medicine, National Institutes of Health. 

[FR Doc. E9–6934 Filed 3–27–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Method of Making a Vaccine 

Description of Technology: Current 

invention describes the methods to 

prepare vaccines, and to use such 

vaccines in the vaccination and 

treatment of human disease, e.g., the 

human immunodeficiency virus (HIV) 

infections and cancer. More specifically, 

the present invention provides a vaccine 

and method for making same which is 

effective to elicit a desired antibody 

against a target antigen comprising a 

primary immunogen and a secondary 

immunogen, wherein the primary 

immunogen is effective to elicit B cell 

receptors (BCRs) that are on the 

maturational pathway of the desired 

antibody and have an intermediate 

degree of somatic mutational diversity, 

and the secondary immunogen 

comprises an epitope of the desired 

target antibody and is effective to 

further diversify the BCRs sufficient to 

form mature BCRs having the identical 

or substantially identical sequence as 

the desired antibody. 

Applications: Treatment and 

prevention of HIV infection. 

Advantages: Novel methods to design 

vaccines for HIV treatment and 

prevention; May also be used for 

designing vaccines for cancer treatment. 

Development Status: In vitro data 

available. 

Market: HIV therapeutics and 

preventatives. 

Inventor: Dimiter S. Dimitrov (NCI). 

Publications: 

1. MY Zhang, Y Shu, S Phogat, X 

Xiao, F Cham, P Bouma, A Choudhary, 

YR Feng, I Sanz, S Rybak, CC Broder, 

GV Quinnan, T Evans, DS Dimitrov. 

Broadly cross-reactive HIV neutralizing 

human monoclonal antibody Fab 

selected by sequential antigen panning 

of a phage display library. J Immunol 

Methods. 2003 Dec;283(1–2):17–25. 

2. MY Zhang, X Xiao, IA Sidorov, V 

Choudhry, F Cham, PF Zhang, P Bouma, 

M Zwick, A Choudhary, DC Montefiori, 

CC Broder, DR Burton, GV Quinnan Jr, 

DS Dimitrov. Identification and 

characterization of a new cross-reactive 

human immunodeficiency virus type 1- 

neutralizing human monoclonal 

antibody. J Virol. 2004 Sep;78(17):9233– 

9242. 

3. Z Zhu, AS Dimitrov, KN Bossart, G 

Crameri, KA Bishop, V Choudhry, BA 

Mungall, YR Feng, A Choudhary, MY 

Zhang, Y Feng, LF Wang, X Xiao, BT 

Eaton, CC Broder, DS Dimitrov. Potent 

neutralization of Hendra and Nipah 

viruses by human monoclonal 

antibodies. J Virol. 2006 Jan;80(2):891– 

899. 

4. MY Zhang, V Choudhry, IA 

Sidorov, V Tenev, BK Vu, A Choudhary, 

H Lu, GM Stiegler, HW Katinger, S 

Jiang, CC Broder, DS Dimitrov. Selection 

of a novel gp41-specific HIV-l 

neutralizing human antibody by 

competitive antigen panning. J Immunol 

Methods. 2006 Dec 20;317(1–2):21–30. 

5. V Choudhry, MY Zhang, IA 

Sidorov, JM Louis, I Harris, AS 

Dimitrov, P Bouma, F Cham, A 

Choudhary, SM Rybak, T Fouts, DA 

Montefiori, CC Broder, GV Quinnan Jr, 

DS Dimitrov. Cross-reactive HIV–1 

neutralizing monoclonal antibodies 

selected by screening of an immune 

human phage library against an 

envelope glycoprotein (gpI40) isolated 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices 14139 

from a patient (R2) with broadly HIV-l 

neutralizing antibodies. Virology. 2007 

Jun 20;363(1):79–90. 

6. Z Zhu, S Chakraborti, Y He, A 

Roberts, T Sheahan, X Xiao, LE Hensley, 

P Prabakaran, B Rockx, IA Sidorov, D 

Corti, L Vogel, Y Feng, JO Kim, LF 

Wang, R Baric, A Lanzavecchia, KM 

Curtis, GJ Nabel, K Subbarao, S Jiang, 

DS Dimitrov. Potent cross-reactive 

neutralization of SARS coronavirus 

isolates by human monoclonal 

antibodies. Proc Natl Acad Sci USA. 

2007 Jul 17;104(29):12123–12128. 

7. Z Zhu, KN Bossart, KA Bishop, G 

Crameri, AS Dimitrov, JA McEachern, Y 

Feng, D Middleton, LF Wang, CC 

Broder, DS Dimitrov. Exceptionally 

potent cross-reactive neutralization of 

Nipah and Hendra viruses by a human 

monoclonal antibody. J Infect Dis. 2008 

Mar 15;197(6):846–853. 

8. MY Zhang, BK Vu, A Choudhary, 

H Lu, M Humbert, H Ong, M Alam, RM 

Ruprecht, G Quinnan, S Jiang, DC 

Montefiori, JR Mascola, CC Broder, BF 

Haynes, DS Dimitrov. Cross-reactive 

human immunodeficiency virus type 1- 

neutralizing human monoclonal 

antibody which recognizes a novel 

conformational epitope on gp41 and 

lacks reactivity against self antigens. J 

Virol. 2008 Jul;82(14):6869–6879. 

Patent Status: U.S. Provisional 

Application No. 61/104,706 filed 11 Oct 

2008 (HHS Reference No. E–322–2008/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Sally Hu, Ph.D.; 

301–435–5606; HuS@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize this method. Please 

contact John D. Hewes, Ph.D. at 301– 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Anti-Hepatitis C Virus Activity of the 

Protein Scytovirin (SVN) 

Description of Technology: The 

invention provides compositions and 

methods of use for potent anti-HCV 

protein scytovirin to prevent and treat 

HCV infections. Currently there is 

neither effective treatment nor vaccine 

against HCV infection and chronic HCV 

infection may lead to liver cancer and 

death. Scytovirin can be used alone or 

in combination with other anti-HCV 

drugs for HCV treatment and 

prevention. 

Applications: The treatment and 

prevention of HCV infections. 

Advantages: Potent anti-HCV activity; 

Can be applied both systematically or 

locally. 

Development Status: In vitro data 

available. 

Market: HCV therapeutics and 

preventatives. 

Inventors: Barry R. O’Keefe et al. 

(NCI). 

Publications: Data collection and 

manuscripts may be submitted in 2009. 

Patent Status: U.S. Provisional 

Application No. 61/137,511 filed 31 Jul 

2008 (HHS Reference No. E–161–2008/ 

0–US–01). 

Related Technology: HHS Reference 

No. E–017–2002/0—Scytovirins and 

Related Conjugates, Antibodies, 

Compositions, Nucleic Acids, Vectors, 

Host Cells, Methods of Production and 

Methods of Using Scytovirin. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Sally Hu, Ph.D.; 

301–435–5606, HuS@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute CCR 

Molecular Targets Development 

Program is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact John D. Hewes, Ph.D. at 301– 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Dated: March 19, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–6933 Filed 3–27–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Treatment of Schistosomiasis Using 

Substituted Oxadiazole 2-Oxides 

Description of Technology: Available 

for licensing and commercial 

development are pharmaceutical 

compositions and methods for the 

treatment of schistosomiasis in 

mammals. The various compositions are 

based on a number of compounds 

derived from 1,2,5-oxadiazole that are 

potent inhibitors of thioredoxin 

glutathione reductase (TGR), a critical 

parasite redox protein. 

Schistosomiasis is a chronic disease 

caused by trematode flatworms of the 

genus Schistosoma, including S. 

mansoni, S. japonicum and S. 

haematobium. Adult schistosome 

parasites live in an aerobic environment 

within human hosts, and therefore must 

have effective mechanisms to maintain 

cellular redox balance. Additionally, the 

worms must be able to evade reactive 

oxygen species generated by the host’s 

immune response. In most eukaryotes 

there are two major systems to detoxify 

reactive oxygen species, one based on 

the tripeptide glutathione and the other 

based on the protein thioredoxin. 

Glutathione reductase (GR) reduces 

glutathione disulfide, whereas 

thioredoxin reductases (TrxR) are 

pivotal in the Trx-dependent system. It 

was recently discovered that specialized 

TrxR and GR enzymes are absent in 

schistosomes. Instead, they are replaced 

by the unique multifunctional enzyme 

TGR. This reliance on a single enzyme 

for both glutathione disulfide and 

thioredoxin reduction suggests that the 

parasite’s redox systems are subject to a 

bottleneck dependence on TGR, and 

that TGR represents a potentially 

important drug target. 

Schistosomiasis remains a major and 

neglected health problem in many 

tropical areas. The health burden 

resulting from schistosomiasis is 

estimated to include more than 200 

million people infected, 779 million at 

risk of infection, 280,000 deaths 

annually, and more than 20 million 

individuals experiencing high 

morbidity. Clinical manifestations of 

schistosomiasis infection include 

abdominal pain, cough, diarrhea, 


sroberts on PROD1PC70 with NOTICES